Presenters provide an in-depth analysis of the latest pharmacologic treatments for alcohol-associated liver disease (ALD) and alcohol-associated hepatitis (AH). Speakers focus on understanding the mechanisms, efficacy, and safety profiles of current medications as well as promising therapies in development. The session aims to equip health care professionals with knowledge to enhance patient outcomes through cutting-edge pharmacotherapy interventions.
Discuss insights into the current pharmacotherapy landscape for ALD and AH, including the action mechanisms, indications, contraindications, and side effect management to ensure optimal patient care.
Summarize emerging therapies in the pipeline for ALD and AH, including their potential impact on the disease course, quality of life, and long-term outcomes based on the latest clinical trial data.
Review how to critically appraise new research and developments in pharmacotherapy for ALD and AH, focusing on the integration of evidence-based treatments into clinical practice and navigating the challenges associated with adopting novel medications.